Rx Class-Of-Trade Price Differences May Not Be Anti-Competitive - FTC

05 Apr 1999

• By The Pink Sheet

Differential pricing within the pharmaceutical industry could be explained by "competitive price discrimination" rather than by anti-competitive actions, a Federal Trade Commission staff report on changes in the pharmaceutical industry states.

Rx Class-Of-Trade Price Differences May Not Be Anti-Competitive - FTC

More from Archive

More from Pink Sheet